Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy for Small Bowel Adenocarcinoma (BALLAD)
NCT02502370Phase 3Unknown
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Primary completion
- Sep 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, oxaliplatin and capecitabine in small bowel adenocarcinoma (SBA) (4 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Disease-Free Survival at 3 years. Status: unknown.
02
Drugs
fluorouraciloxaliplatincapecitabine
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on NCT02502370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502370.